{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Schmidt KG"],"funding":["Hector Stiftung","Bavarian State Ministry of Science and the Arts","Friedrich-Alexander-Universität Erlangen-Nürnberg"],"pagination":["1657-1667"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10106868"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["51(6)"],"pubmed_abstract":["<h4>Purpose</h4>The Ad26.COV2.S vaccine is a replication-incompetent human adenovirus type 26 vector encoding the SARS-CoV-2 spike protein. In a phase 1-2a trial, a single dose of Ad26.COV2.S induced SARS-CoV-2 spike-specific antibodies in ≥ 96% of healthy adults. To investigate vaccine immunogenicity in HIV-1-infection, we measured SARS-CoV-2 spike-specific antibodies in Ad26.COV2.S vaccinated HIV-1-infected patients and analyzed the presence of pre-existing Ad26 neutralizing antibodies.<h4>Methods</h4>We included all Ad26.COV2.S vaccinated HIV-1-infected patients of Erlangen HIV cohort fulfilling all inclusion criteria. The study cohort consisted of 15 HIV-1-infected patients and three HIV-1-uninfected subjects who received the Ad26.COV2.S vaccine between April and November 2021. Pre-vac"],"journal":["Infection"],"pubmed_title":["Detection of pre-existing neutralizing antibodies against Ad26 in HIV-1-infected individuals not responding to the Ad26.COV2.S vaccine."],"pmcid":["PMC10106868"],"funding_grant_id":["Corona research program","M2102"],"pubmed_authors":["Steininger P","Schmidt KG","Schonau V","Nganou-Makamdop K","Harrer T","Korn K","Kleyer A","Simon D","Schett G","Knobloch CS","Harrer EG"],"additional_accession":[]},"is_claimable":false,"name":"Detection of pre-existing neutralizing antibodies against Ad26 in HIV-1-infected individuals not responding to the Ad26.COV2.S vaccine.","description":"<h4>Purpose</h4>The Ad26.COV2.S vaccine is a replication-incompetent human adenovirus type 26 vector encoding the SARS-CoV-2 spike protein. In a phase 1-2a trial, a single dose of Ad26.COV2.S induced SARS-CoV-2 spike-specific antibodies in ≥ 96% of healthy adults. To investigate vaccine immunogenicity in HIV-1-infection, we measured SARS-CoV-2 spike-specific antibodies in Ad26.COV2.S vaccinated HIV-1-infected patients and analyzed the presence of pre-existing Ad26 neutralizing antibodies.<h4>Methods</h4>We included all Ad26.COV2.S vaccinated HIV-1-infected patients of Erlangen HIV cohort fulfilling all inclusion criteria. The study cohort consisted of 15 HIV-1-infected patients and three HIV-1-uninfected subjects who received the Ad26.COV2.S vaccine between April and November 2021. Pre-vac","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Dec","modification":"2026-06-03T13:27:37.724Z","creation":"2025-02-19T04:00:33.102Z"},"accession":"S-EPMC10106868","cross_references":{"pubmed":["37067754"],"doi":["10.1007/s15010-023-02035-6"]}}